Over the next two years, Cancer Genetics' genomic laboratory in Hyderabad, India, expects to analyze several thousand samples provided by ReproCell.
An increase in test order volume was offset by lower reimbursement from both Medicare and third-party payors.
Revenue from SelectOne clinical trials services and acquisitions drove the year over year growth.
Once an oncologist decides a patient needs chemotherapy, Moffitt will test for PGx markers that might hinder his or her ability to metabolize anti-vomiting and pain meds.
The partners will study the association between genetic variants and chemotherapy side effects to find biomarkers for an upcoming NGS pharmacogenomics panel.
The conditional licensure is the latest for the firm's FISH-based HPV-Associated test for cervical cancer.
The company borrowed $2 million pursuant to an amendment to a $12 million credit agreement. It also said that it has until June 19 to meet certain listing requirements.
About 19 million ACPN members will now have access to Cancer Genetics' cancer diagnostic services through their insurers.
Revenue from the firm's ResponseDX test jumped 16 percent in the fourth quarter of 2014 and 22 percent for the full year.
The company's biopharma business grew 280 percent year over year, including contributions from Gentris, which Cancer Genetics bought last summer.
Nature News examines how science in the UK may fare as Boris Johnson, the next prime minister, pursues Brexit.
CNN reports that Immigration and Customs Enforcement in the US has expanded its DNA testing to seven sites along the southern border.
In PNAS this week: role for exosomes in neuronal circuit development, tuberculosis pathogen enzymes, and more.
Undoing Obamacare protections could affect people's willingness to undergo genetic testing, Sarah Lawrence College's Laura Hercher and the University of Iowa College of Law's Anya Prince write at BuzzFeed News.